title: [Tumor lysis syndrome].
abstract: Recently, the ASCO guideline has added TLS. Prevention and recognition of the disease and state are important. Molecular targeting drugs, small molecule tyrosine kinase inhibitors and monoclonal antibodies induced rapid regression of the tumors and carry a risk of TLS. The recognition of the disease which may have a high risk of TLS and laboratory TLS is important.
authors.affiliation: Division of Medical Oncology, Hematology, Ambulatory Therapy Center, Tokyo, Japan
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Hatake
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D006801:Humans; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents